Preparation method of nanoparticles with multiple treatment functions

By accurately regulating the reaction conditions and design, hollow mesoporous polydopamine nanoparticles were synthesized, combining Cu+ and Ce6 to form multifunctional nanoparticles CPCF NPs, solving the problems of nanoparticles distribution in vivo and tumor microenvironment responsiveness, and realizing the tumor area Enrichment and controllable release improve drug utilization and inhibit tumor growth.

CN119033730APending Publication Date: 2024-11-29JILIN UNIV FIRST HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411250826.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The distribution of existing nanoparticles with single treatment functions in the body and tumor sites is uncertain, making it difficult to completely eliminate tumor cells, and is inefficient in microenvironment of slightly acidic tumors, and its safety and long-term circulating toxicity have not been effectively solved.

Method used

By accurately regulating the reaction conditions and design, hollow mesoporous polydopamine nanoparticles were synthesized, giving them multi-enzyme activity and pH sensitive response. Combined with Cu+ and Ce6, multi-functional nanoparticles CPCF NPs are formed to achieve responsiveness to the tumor microenvironment. and controllable release, enhancing drug utilization and reducing toxic side effects.

Benefits of technology

CPCF NPs show excellent tumor microenvironment responsiveness in specific redox environments, achieving enrichment and controllable release of tumor areas, improving drug utilization, reducing circulating metabolic toxicity side effects, and through multimodal collaborative treatment Effectively inhibits tumor growth.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033730A_ABST
    Figure CN119033730A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and particularly relates to a preparation method of nano particles with multiple treatment functions, F127, TMB, CuCl22H2O and Ce6 are used as raw materials, a multifunctional nano particle CPCF NPs is synthesized through a preparation process of MPDA NPs, a preparation process of CP NPs, a preparation process of CPC NPs and a preparation process of CPCF NPs in sequence, and the multifunctional nano particle CPCF NPs is used as a carrier to greatly improve the drug loading efficiency. The CPCF NPs shows excellent stimulation responsiveness under the stimulation of a tumor microenvironment and exogenous laser, multi-mode synergistic treatment effectively inhibits tumor growth, and the synthesis construction strategy of the nano particles provides precious guidance for the development of subsequent related nano particles, and has broad application prospects. And a new choice is provided for a mild, safe and efficient tumor nano treatment mode.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and in particular relates to a method for preparing nanoparticles with multiple therapeutic functions. Background Art

[0002] The construction and application of nanoparticles have developed rapidly in biomedicine, covering many fields such as drug delivery, bone and tissue engineering, cell adhesion, antibacterial applications, recognition and fixation of biomolecules, molecular imprinting technology and catalyst carriers. In recent years, nanoparticles have shown great advantages in cancer treatment due to their excellent properties.

[0003] As a widely used photothermal agent, polydopamine (PDA) has the advantages of high photothermal conversion efficiency, simple preparation, excellent drug loading capacity and low cytotoxicity. However, PDA nanoparticles with a single therapeutic function cannot confirm their distribution in the body and tumor site, nor can they completely eliminate tumor cells. Therefore, PDA is often combined with other imaging agents and therapeutic agents to maximize the killing of tumor cells and provide more comprehensive tumor information.

[0004] As a safe and effective in situ tumor treatment strategy widely used in recent years, chemodynamic therapy (CDT) induces tumor cell death by producing excessive reactive oxygen species represented by hydroxyl radicals in the tumor cell microenvironment. The most representative method to achieve CDT is the Fenton reaction based on Fe-based nanomaterials. 2+ The catalytic Fenton reaction is only effective in a strong acid environment (pH 2-4), and the reaction rate is low even at an ideal pH value. In physiological neutral conditions and the slightly acidic tumor microenvironment, the reaction rate and therapeutic efficiency are even lower. + The Fenton-like reaction in slightly acidic medium is very efficient, and the maximum reaction rate is higher than that of Fe 2+ About 160 times, which is enough to prove that in the slightly acidic tumor microenvironment, Cu + The effect of CDT caused by the production of reactive oxygen species is better. In the practice of CDT, its efficacy and safety are the highest priority. Although there will be excess H2O2 in the weakly acidic pH unique to the tumor microenvironment to provide raw materials for CDT, the concentration of GSH is also much higher than that of normal cells, which consumes a large amount of •OH used for CDT, thereby affecting the efficiency of CDT. Therefore, consuming or even depleting GSH is an effective strategy to enhance CDT. Previous studies and application practices have shown that single CDT therapy cannot completely eliminate tumor cells, and it is difficult to prevent further metastasis of cancer cells. Therefore, it is urgent to develop multimodal synergistic nanoparticles based on efficient CDT for the treatment of tumors.

[0005] Chlorin E6 (Ce6) is a photosensitizer widely used in photodynamic therapy and in vivo fluorescence imaging. It has low cytotoxicity and good deep tissue penetration. Under 650 nm laser irradiation, Ce6 accumulated in target locations such as near tumors can be activated to induce the production of ROS, thereby promoting cell apoptosis. However, its own hydrophobicity and hypoxia in the tumor microenvironment will seriously affect its efficacy.

[0006] With the increasing use of nanoparticles, their safety in vivo application and long-term circulating toxicity have also received attention. How to build a safe and reliable system while ensuring the original functions of nanoparticles deserves further exploration by researchers. Summary of the invention

[0007] The purpose of the present invention is to provide a method for preparing nanoparticles with multiple therapeutic functions. Hollow mesoporous polydopamine nanoparticles are successfully synthesized by precisely controlling the feed ratio. As a carrier, the drug loading efficiency is greatly increased. The large specific surface area and abundant active groups lay a solid foundation for subsequent modification thereof to solve the problems existing in the above-mentioned background technology.

[0008] To achieve the above objectives, this application is implemented through the following technical solutions:

[0009] A method for preparing nanoparticles with multiple therapeutic functions, comprising the following steps:

[0010] S1. Preparation of MPDA NPs:

[0011] Dissolve Tris powder in deionized water to obtain a Tris solution, mix deionized water and anhydrous ethanol to obtain a mixed solution, then add F127, TMB, Tris solution and dopamine hydrochloride to the mixed solution in sequence, stir in a magnetic stirrer for 24-60 h and then centrifuge and filter, wash the filtrate with a washing solution to obtain MPDA NPs, disperse the MPDA NPs in deionized water to obtain an MPDA NPs solution, and store in a 4°C refrigerator;

[0012] S2. Preparation of CP NPs:

[0013] The CuCl2•2H2O solution and the MPDA NPs solution obtained in step S1 are mixed evenly and then added to a mixed solution of Tris-HCl solution and anhydrous ethanol, stirred in a magnetic stirrer for 2-4 h and then centrifuged and filtered, the filtrate is washed with a washing solution to obtain CP NPs, and the CP NPs are dispersed in anhydrous ethanol to obtain a CP NPs solution;

[0014] S3. Preparation of CPC NPs:

[0015] The CP NPs solution prepared in step S2 was mixed evenly with the Ce6 solution, stirred in an ethanol solution for 10-15 h, and then centrifuged and filtered. The filtrate was washed with a washing solution to obtain CPC NPs. The CPC NPs were dispersed in anhydrous ethanol to obtain a CPC NPs solution, which was sealed and stored in a refrigerator at 4°C away from light;

[0016] S4. Preparation of CPCF NPs:

[0017] The CPC NPs solution prepared in step S3 was mixed evenly with the F127 solution, stirred in an ethanol solution for 10-15 h, and then centrifuged and filtered. The filtrate was washed with a washing solution to obtain CPCF NPs.

[0018] Furthermore, the washing liquids used in steps S1 to S4 are respectively: deionized water, deionized water, anhydrous ethanol, and a washing liquid obtained by mixing ethanol and acetone in a volume ratio of 2:1.

[0019] Furthermore, the centrifugal filtration in steps S1 to S4 is performed at 8000 rpm for 15 min.

[0020] Furthermore, the steps of washing with washing liquid in steps S1 to S4 are all to disperse the filtrate in the washing liquid, sonicate for 30 min, and then centrifuge at 8000 rpm for 15 min.

[0021] Furthermore, in step S1, the mass ratio of F127 to TMB is 10:1-1:10.

[0022] Furthermore, in step S2, the mass ratio of CuCl2•2H2O to MPDA NPs is 5:1-1:5.

[0023] Furthermore, in step S3, the mass ratio of Ce6 to CP NPs is 10:3-3:10.

[0024] Further, in step S4, the mass ratio of F127 to CPC NPs is 3:1-5:2.

[0025] The beneficial effects of the present invention are:

[0026] This technical solution successfully synthesized multifunctional nanoparticles CPCFNPs through precise control of reaction conditions and ingenious design. In a unique redox environment, copper ions with different valence states accurately filled and modified the hollow and mesoporous structures of MPDA NPs, endowing CPCF NPs with multi-enzyme activities of catalase, peroxidase and glutathione peroxidase, making them excellent in tumor microenvironment (H2O2 and GSH) responsiveness. The specificity of the CPCF NPs structure also increases its sensitive responsiveness to pH. The graded disintegration state at different pH (different parts of the body) helps to achieve enrichment and controllable release in the tumor area, improving drug utilization while reducing the toxic side effects caused by circulating metabolism. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 Schematic diagram of the preparation of nanoparticles with multiple therapeutic functions of the present invention.

[0028] Figure 2 Transmission electron microscope images of polydopamine nanoparticles when TMB / F127 = 0 (a), 0.2 (b), 0.4 (c), 0.6 (d), 0.8 (e), and 0.9 (f).

[0029] Figure 3 Related photos of HMPDA NPs, including: (a) transmission electron microscopy photo of HMPDA NPs; (b) local magnification, the red circle shows the magnified nanoparticles; (c) scanning electron microscopy photo of HMPDA NPs; (d) electron microscopy photo of HMPDA NPs after freeze-fracture.

[0030] Figure 4 The corresponding photos are when TMB / F127= 2, including the transmission electron microscopy photo (a) and scanning electron microscopy photo (b) of HMPDA NPs; the transmission electron microscopy photos of HMPDA NPs when TMB / F127= 5 (c, d).

[0031] Figure 5 Transmission electron microscopy images of CP NPs synthesized when different concentrations of HMPDA were added, where (a) HMPDA = 0.5 mL; (b) HMPDA = 0.8 mL; (c) HMPDA = 1.0 mL; (d) HMPDA = 1.2 mL; (e) HMPDA = 1.5 mL; Scale bar: 200 nm.

[0032] Figure 6 Transmission electron microscopy images of CPCF NPs at different magnifications (ac), with the scale bar as shown in the figure. DETAILED DESCRIPTION

[0033] The technical solution of the present invention is described in detail below in conjunction with the accompanying drawings. The following embodiments are merely exemplary and can only be used to explain and illustrate the technical solution of the present invention, but cannot be construed as limiting the technical solution of the present invention.

[0034] like Figures 1 to 6 As shown, the present application provides a method for preparing nanoparticles with multiple therapeutic functions, using the following steps:

[0035] This technical solution successfully synthesized hollow mesoporous polydopamine nanoparticles by precisely controlling the feed ratio, which greatly increased the drug loading efficiency as a carrier. The large specific surface area and abundant active groups laid a solid foundation for subsequent modification.

[0036] Preparation of MPDA NPs:

[0037] The Tris powder was dissolved in deionized water to obtain a Tris solution, and the deionized water and anhydrous ethanol were mixed to obtain a mixed solution. Then, F127, TMB, Tris solution and dopamine hydrochloride were added to the mixed solution in sequence, and the mixture was stirred in a magnetic stirrer for 24-60 hours and then centrifuged (8000 rpm, 15 min). The filtrate was washed three times with a washing solution, which was obtained by mixing ethanol and acetone in a volume ratio of 2:1. The steps of washing with the washing solution are as follows: the filtrate was dispersed in the washing solution, ultrasonicated for 30 minutes, and then centrifuged at 8000 rpm for 15 minutes to obtain MPDA NPs. The MPDA NPs were dispersed in deionized water to obtain an MPDA NPs solution, which was stored in a refrigerator at 4 °C. The morphology of the synthesized MPDANPs can be adjusted by adjusting the mass ratio of F127 to TMB.

[0038] Preparation of CP NPs:

[0039] In the redox synthesis system, copper ions of different valence states are used to modify and fill the hollow and mesoporous structures. + With Cu 2+ The mutual conversion of elemental copper in the tumor microenvironment endows the nanoparticles with three kinds of enzyme activities: catalase, peroxidase and glutathione peroxidase, which can not only convert the less toxic H2O2 into the more toxic •OH, but also consume a large amount of GSH.

[0040] The CuCl2•2H2O solution and the MPDA NPs solution obtained above were mixed evenly and then added to a mixed solution of Tris-HCl solution and anhydrous ethanol. After stirring in a magnetic stirrer for 2-4 h, the mixture was centrifuged and filtered (8000 rpm, 15 min). The filtrate was washed three times with a washing solution, which was obtained by mixing ethanol and acetone in a volume ratio of 2:1. The washing steps of the washing solution were as follows: the filtrate was dispersed in the washing solution, ultrasonicated for 30 min, and then centrifuged at 8000 rpm for 15 min to obtain CPNPs, and the CP NPs were dispersed in anhydrous ethanol to obtain a CP NPs solution. The morphology of CP NPs can be adjusted by adjusting the mass ratio of CuCl2•2H2O to MPDA, and the particle size can be controlled by controlling the reaction time.

[0041] Preparation of CPC NPs:

[0042] Ce6 was successfully loaded on the nanoparticles through the adsorption of PDA and the electrostatic interaction between metal cations. Compared with the free state, loading on a carrier with excellent hydrophilic properties not only increases the solubility of Ce6, but also improves the delivery efficiency of Ce6 and the drug concentration in the targeted area. At the same time, the catalase-like properties of the original nanoparticles can produce oxygen in the acidic microenvironment of the tumor, continuously supply oxygen to Ce6, amplify the effect of introducing exogenous laser irradiation photodynamic therapy, and achieve the joint cooperation and amplification of the therapeutic effect of the components inside the nanoparticles. Pluronic F127 has been widely used as a drug adjuvant. It is an amphiphilic polymer in the family of polyoxyethylene-polyoxypropylene-polyoxyethylene (PEO-PPO-PEO) copolymers, containing hydrophilic PEO chains and hydrophobic PPO chains. In this scheme, it is used as the outermost layer to form a complete nanocomposite CPCF NPs. The hydrophilic PEO chain can bind to the surface active group of dopamine, and the hydrophobic PPO chain binds to Ce6. It not only increases the solubility of the overall nanocomplex and improves biocompatibility, but also enhances cell internalization and tumor treatment effects.

[0043] The prepared CP NPs solution and Ce6 solution were mixed evenly, stirred in an ethanol solution for 10-15h, and then centrifuged (8000 rpm, 15 min). The filtrate was washed three times with a washing solution, which was obtained by mixing ethanol and acetone in a volume ratio of 2:1. The washing step of the washing solution is to disperse the filtrate in the washing solution, ultrasonicate for 30 min, and then centrifuge at 8000 rpm for 15 min to obtain CPC NPs, disperse CPC NPs in anhydrous ethanol to obtain CPC NPs solution, and store it in a sealed and light-proof refrigerator at 4 °C.

[0044] Preparation of CPCF NPs:

[0045] The CPC NPs solution prepared above was mixed evenly with the F127 solution, stirred in an ethanol solution for 10-15h, and then centrifuged (8000 rpm, 15 min). The filtrate was washed three times with a washing solution, which was obtained by mixing ethanol and acetone in a volume ratio of 2:1. The washing steps of the washing solution were as follows: the filtrate was dispersed in the washing solution, ultrasonicated for 30 min, and then centrifuged at 8000 rpm for 15 min to obtain CPCF NPs.

[0046] Example 1

[0047] Preparation of MPDA NPs:

[0048] 60 mL of deionized water was mixed with 60 mL of anhydrous ethanol, and then 0.36 g of F127, 420 µL of TMB (0.86 gmL-1), 10 mL of deionized water containing 90 mg of Tris powder, and 60 mg of dopamine hydrochloride were added to the mixture in sequence. After stirring for 48 h in a magnetic stirrer, the mixture was centrifuged (8000 rpm, 15 min). The nanoparticles were washed three times with a mixture of ethanol and acetone in a volume ratio of 2:1. The specific washing steps were to disperse the nanoparticles in the mixture, ultrasonicate for 30 min, and then centrifuge (8000 rpm, 15 min). Finally, the nanoparticles were dispersed in 20 mL of deionized water and stored in a 4 °C refrigerator. In other embodiments of the present application, the morphology of the synthesized MPDA NPs can be adjusted by adjusting the mass ratio of F127 to TMB, for example, the mass ratio of F127 to TMB is 10:1-1:10.

[0049] Preparation of CP NPs:

[0050] 10 mL CuCl2•2H2O solution (2.5 mg mL -1 ) and 1 mL MPDA NPs (5 mg mL -1 ) and mixed evenly, and added to a mixed solution of 12 mL Tris-HCl solution and 12 mL anhydrous ethanol. After stirring for 2 h in a magnetic stirrer, centrifuge (8000 rpm, 15 min), then wash three times with a mixture of ethanol and water, and finally disperse into 20 mL anhydrous ethanol for later use. In other embodiments of the present application, the morphology of CP NPs can be adjusted by adjusting the mass ratio of CuCl2•2H2O to MPDA, and the particle size can be controlled by controlling the reaction time.

[0051] Preparation of CPC NPs:

[0052] 10 mL of the previously synthesized CP NPs (1 mg mL -1 ) and 20 mL Ce6 (150 µg mL -1 ) solution was mixed evenly, stirred in the ethanol solution for 12 h, and then centrifuged and washed three times to obtain CPC NPs dispersed in 20 mL of anhydrous ethanol, sealed and stored in a refrigerator at 4 ℃ away from light for later use.

[0053] Preparation of CPCF NPs:

[0054] 10 mL of synthesized CPC NPs (1 mg mL -1 ) with 20 ml F127 (1.5 mg mL -1 ) solution was mixed evenly, stirred in ethanol solution for 12 h and then centrifuged and washed three times to obtain CPCF NPs, which were dispersed in 20 mL of deionized water and stored in a sealed refrigerator at 4 ℃ away from light.

[0055] Example 2

[0056] Preparation of MPDA NPs:

[0057] 60 mL of deionized water was mixed with 60 mL of anhydrous ethanol, followed by 0.36 g of F127, 42 µL of TMB (0.86 g mL -1 ), 10 mL of deionized water containing 90 mg of Tris powder, and 60 mg of dopamine hydrochloride were added to the above mixture in sequence, stirred in a magnetic stirrer for 48 h, and then centrifuged (8000 rpm, 15 min), and the nanoparticles were washed three times with a mixture of ethanol and acetone at a volume ratio of 2:1. The specific washing steps were to disperse the nanoparticles in the mixture, ultrasonicate for 30 min, and then centrifuge (8000 rpm, 15 min). Finally, the nanoparticles were dispersed in 20 mL of deionized water and stored in a 4 ° C refrigerator. In other embodiments of the present application, the morphology of the synthesized MPDA NPs can be adjusted by adjusting the mass ratio of F127 to TMB, for example: the mass ratio of F127 to TMB is 10:1-1:10.

[0058] Preparation of CP NPs:

[0059] 10 mL CuCl2•2H2O solution (2.5 mg mL -1 ) with 1 mL MPDA NPs (10 mg mL -1) and mixed evenly, and added to a mixed solution of 12 mL Tris-HCl solution and 12 mL anhydrous ethanol. After stirring for 2 h in a magnetic stirrer, centrifuge (8000 rpm, 15 min), then wash three times with a mixture of ethanol and water, and finally disperse into 20 mL anhydrous ethanol for later use. In other embodiments of the present application, the morphology of CP NPs can be adjusted by adjusting the mass ratio of CuCl2•2H2O to MPDA, and the particle size can be controlled by controlling the reaction time.

[0060] Preparation of CPC NPs:

[0061] 10 mL of the previously synthesized CP NPs (1 mg mL -1 ) and 20 mL Ce6 (500 µg mL -1 ) solution was mixed evenly, stirred in the ethanol solution for 12 h, and then centrifuged and washed three times to obtain CPC NPs dispersed in 20 mL of anhydrous ethanol, sealed and stored in a refrigerator at 4 ℃ away from light for later use.

[0062] Preparation of CPCF NPs:

[0063] 10 mL of synthesized CPC NPs (1 mg mL -1 ) with 20 ml F127 (0.5 mg mL -1 ) solution was mixed evenly, stirred in ethanol solution for 12 h and then centrifuged and washed three times to obtain CPCF NPs, which were dispersed in 20 mL of deionized water and stored in a sealed refrigerator at 4 ℃ away from light.

[0064] Example 3

[0065] Preparation of MPDA NPs:

[0066] 60 mL of deionized water was mixed with 60 mL of anhydrous ethanol, followed by 0.36 g of F127, 4.2 mL of TMB (0.86 g mL -1), 10 mL of deionized water containing 90 mg of Tris powder, and 60 mg of dopamine hydrochloride were added to the above mixture in sequence, stirred in a magnetic stirrer for 48 h, and then centrifuged (8000 rpm, 15 min), and the nanoparticles were washed three times with a mixture of ethanol and acetone at a volume ratio of 2:1. The specific washing steps were to disperse the nanoparticles in the mixture, ultrasonicate for 30 min, and then centrifuge (8000 rpm, 15 min). Finally, the nanoparticles were dispersed in 20 mL of deionized water and stored in a 4 ° C refrigerator. In other embodiments of the present application, the morphology of the synthesized MPDA NPs can be adjusted by adjusting the mass ratio of F127 to TMB, for example: the mass ratio of F127 to TMB is 10:1-1:10.

[0067] Preparation of CP NPs:

[0068] 10 mL CuCl2•2H2O solution (2.5 mg mL -1 ) with 1 mL MPDA NPs (20 mg mL -1 ) and mixed evenly, and added to a mixed solution of 12 mL Tris-HCl solution and 12 mL anhydrous ethanol. After stirring for 2 h in a magnetic stirrer, centrifuge (8000 rpm, 15 min), then wash three times with a mixture of ethanol and water, and finally disperse into 20 mL anhydrous ethanol for later use. In other embodiments of the present application, the morphology of CP NPs can be adjusted by adjusting the mass ratio of CuCl2•2H2O to MPDA, and the particle size can be controlled by controlling the reaction time.

[0069] Preparation of CPC NPs:

[0070] 10 mL of the previously synthesized CP NPs (1 mg mL -1 ) and 20 mL Ce6 (1.5 mg mL -1 ) solution was mixed evenly, stirred in the ethanol solution for 12 h, and then centrifuged and washed three times to obtain CPC NPs dispersed in 20 mL of anhydrous ethanol, sealed and stored in a refrigerator at 4 ℃ away from light for later use.

[0071] Preparation of CPCF NPs:

[0072] 10 mL of synthesized CPC NPs (1 mg mL -1 ) with 20 ml F127 (0.2 mg mL -1 ) solution was mixed evenly, stirred in ethanol solution for 12 h and then centrifuged and washed three times to obtain CPCF NPs, which were dispersed in 20 mL of deionized water and stored in a sealed refrigerator at 4 ℃ away from light.

[0073] This technical solution successfully synthesized multifunctional nanoparticles CPCFNPs through precise control of experimental conditions and ingenious design. In a unique redox environment, copper ions accurately filled and modified the hollow and mesoporous structures of HMPDA NPs with different valence states, endowing CPCF NPs with multi-enzyme activities of catalase, peroxidase and glutathione peroxidase, making them excellent tumor microenvironment (H2O2 and GSH) responsive. The specificity of the CPCF NPs structure also increases its sensitive responsiveness to pH. The graded disintegration state at different pH (different parts of the body) helps to achieve enrichment and controllable release in the tumor area, improving drug utilization while reducing the toxic side effects caused by circulating metabolism.

[0074] The loading of photosensitizer Ce6 not only introduces the photodynamic therapy mode, but also increases the fluorescence imaging function of nanoparticles in vivo, achieving the initial goal of visually guided treatment.

[0075] In addition, the catalase-like activity of CPCF NPs decomposes the highly expressed H2O2 in the tumor microenvironment to produce O2, which continuously provides protection for the photodynamic therapy mode of Ce6. 2+ Consumes GSH and converts it into Cu + , Cu + In an acidic environment, an efficient Fenton-like reaction occurs to convert Cu 2+ , the self-disproportionation reaction can also generate elemental copper, realizing a cascade reaction inside the nanoparticles, self-production and sales, and efficient collaboration.

[0076] Based on the chemodynamic therapy mode, photodynamic therapy mode and copper ion toxicity-mediated chemotherapy mode, the introduction of a mild photothermal therapy mode not only ensures the safety of surrounding normal tissues and organs to the greatest extent, but also improves the effectiveness of other treatment modes.

[0077] In vitro and in vivo experiments have shown that CPCF NPs exhibit excellent stimulus responsiveness under the stimulation of tumor microenvironment and exogenous laser, and multi-modal synergistic treatment effectively inhibits tumor growth. The synthetic construction strategy of this nanoparticle provides valuable guidance for the subsequent development of related nanoparticles, and also provides a new option for mild, safe and efficient tumor nanotherapy mode.

[0078] The above are preferred implementation modes of the present invention. The above show and describe the basic principles of the present invention and the advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for illustrating the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, and these changes and improvements shall fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. A method for preparing nanoparticles with multiple therapeutic functions, characterized in that: Use the following steps: S1. Preparation of MPDA NPs: Dissolve Tris powder in deionized water to obtain a Tris solution, mix deionized water and anhydrous ethanol to obtain a mixed solution, then add F127, TMB, Tris solution and dopamine hydrochloride to the mixed solution in sequence, stir in a magnetic stirrer for 24-60 h and then centrifuge and filter, wash the filtrate with a washing solution to obtain MPDA NPs, disperse the MPDA NPs in deionized water to obtain an MPDA NPs solution, and store in a 4°C refrigerator; S2. Preparation of CP NPs: The CuCl2•2H2O solution and the MPDA NPs solution obtained in step S1 are mixed evenly and then added to a mixed solution of ris-HCl solution and anhydrous ethanol, stirred in a magnetic stirrer for 2-4 hours and then centrifuged and filtered, the filtrate is washed with a washing solution to obtain CPNPs, and the CP NPs are dispersed in anhydrous ethanol to obtain a CP NPs solution; S3. Preparation of CPC NPs: The CP NPs solution prepared in step S2 was mixed evenly with the Ce6 solution, stirred in an ethanol solution for 10-15 h, and then centrifuged and filtered. The filtrate was washed with a washing solution to obtain CPC NPs. The CPC NPs were dispersed in anhydrous ethanol to obtain a CPC NPs solution, which was sealed and stored in a refrigerator at 4°C away from light; S4. Preparation of CPCF NPs: The CPC NPs solution prepared in step S3 was mixed evenly with the F127 solution, stirred in an ethanol solution for 10-15 h, and then centrifuged and filtered. The filtrate was washed with a washing solution to obtain CPCF NPs.

2. The method for preparing nanoparticles with multiple therapeutic functions according to claim 1, characterized in that: The washing liquids used in steps S1 to S4 are respectively: deionized water, deionized water, anhydrous ethanol, and a washing liquid obtained by mixing ethanol and acetone in a volume ratio of 2:

1.

3. The method for preparing nanoparticles with multiple therapeutic functions according to claim 1, characterized in that: The centrifugal filtration in steps S1 to S4 was performed at 8000 rpm for 15 min.

4. The method for preparing nanoparticles with multiple therapeutic functions according to claim 1, characterized in that: The steps of washing with washing liquid in steps S1 to S4 are all to disperse the filtrate in the washing liquid, sonicate for 30 min, and then centrifuge at 8000 rpm for 15 min.

5. The method for preparing nanoparticles with multiple therapeutic functions according to claim 1, characterized in that: In step S1, the mass ratio of F127 to TMB is 10:1-1:

10.

6. The method for preparing nanoparticles with multiple therapeutic functions according to claim 1, characterized in that: In step S2, the mass ratio of CuCl2•2H2O to MPDA NPs is 5:1-1:

5.

7. The method for preparing nanoparticles with multiple therapeutic functions according to claim 1, characterized in that: In step S3, the mass ratio of Ce6 to CP NPs is 10:3-3:

10.

8. The method for preparing nanoparticles with multiple therapeutic functions according to claim 1, characterized in that: In step S4, the mass ratio of F127 to CPC NPs is 3:1-5:2.